Biomarker for Cystic Fibrosis

NCT02710383 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2023-02-10

No results posted yet for this study

Summary

International, multicenter, observational, longitudinal study to identify biomarker/s for Cystic fibrosis and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

Conditions

  • Chronic Nasal Congestion
  • Lung Infection
  • Breathlessness
  • Clubbing Toes
  • Meconium Ileus
  • Failure to Thrive
  • Pancreatitis

Sponsors & Collaborators

  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Peter Bauer, Prof. Dr. · Centogene GmbH

Eligibility

Min Age
2 Months
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Albania
  • Georgia
  • India
  • Pakistan
  • Sri Lanka

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02710383 on ClinicalTrials.gov